top of page

Discussing the MIRASOL ovarian cancer data with Immunogen at #ASCO23

Immunogen CEO Mark Enyedy describes Elahere’s MIRASOL trial result and what it means for ovarian cancer and ADCs.



Join the BiotechTV mailing list

Thanks for subscribing!

bottom of page